Clinical trial
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally…
NCT00301899 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00301899 |
|---|---|
| Title | Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab |
| Official title | A Phase II Study to Evaluate the Efficacy and Safety Using Combined Monoclonal Antibodies, Trastuzumab and Pertuzumab in Subjects With Her-2 Overexpressed Locally Advanced and Metastatic Breast Cancer |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | pertuzumab, trastuzumab |
| Enrollment | 37 |
| Start date | Dec 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Mar 13, 2006 |
| Last update posted | Mar 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: